|Bid||130.36 x 100|
|Ask||130.72 x 200|
|Day's Range||130.06 - 133.59|
|52 Week Range||92.65 - 140.52|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||153.75|
Cannabis stocks took a dive last week after Attorney General Jeff Sessions announced he was rolling back Obama-era federal policies that were hands-off when it came to states moving to legalize marijuana. Is this a reason to sell or a buying opportunity? Todd Harrison, Founding Partner and Chief Investment Officer at CB1 Capital Management, gives us the lowdown.
Back in April, I talked about how GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) was one of the best plays on medical marijuana. Considering the way the cannabinoids work, it makes sense that the main application for medical marijuana would be for neurological disorders — something GWPH was quick to latch on to. GWPH stock has certainly had its trying times — falling on reports stating that medical cannabis could take a way billions of dollars in sales from the pharmaceutical industry for the different conditions it can treat, including epilepsy.
Australia earlier this month joined the growing list of nations that have legalized medical marijuana. The Marijuana Index is a series of equally weighted stock indexes that track the leading cannabis stocks in the U.S. and Canada. GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), with a market cap of $3.34 billion, produces a multiple sclerosis treatment using nabiximols, an herbal preparation containing a defined quantity of specific cannabinoids with potential analgesic activity.
Marijuana can reduce seizures in epilepsy patients, but another drug in clinical studies may work even better.
To say marijuana stocks like Canopy Growth Corp (OTCMKTS:TWMJF), Aurora Cannabis Inc (OTCMKTS:ACBFF) and even GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) have been a little raucous lately would be an understatement. The Obama era’s Drug Enforcement Agency had said (more or less) it wasn’t going to bother taking aim at small-time violations of the federal law that technically still outlaws it in an environment where several states have legalized it. It probably isn’t worth Sessions’ and the DEA’s time and resources to pursue it — and it doesn’t appear the Department of Justice intends to apply a full-court press on the matter — but if it’s a law, it’s a law, and Sessions took an oath to uphold all the laws of the land.
Collaboration agreements announced by companies like Sangamo (SGMO) and the submission of a regulatory application for GW's Epidiolex were the key highlights this week in the biotech sector.
Looking to enhance your portfolio with high-growth, financially-robust stocks, but not sure where you should even begin? Stocks such as TG Therapeutics and Radius Health are deemed to be superiorRead More...
Despite early fears, it turned out 2017 was a pretty hot year for marijuana stocks. “This is a year where the patient were rewarded, which is not that surprising to me,” Alan Brochstein, founder of 420 ...
Look for this name to jump quickly in popularity in 2018 as investors players search for a convenient way to play the marijuana niche.
LONDON, UK / ACCESSWIRE / January 02, 2018 / Active-Investors.com has just released a free research report on GW Pharma PLC (NASDAQ: GWPH ). If you want access to this report all you need to do is sign ...
Categories: Yahoo FinanceGet free summary analysis GW Pharmaceuticals Plc reports financial results for the quarter ended September 30, 2017. Highlights Summary numbers: Revenues of USD 2.80 million, Net Earnings of USD -54.12 million. Gross margins narrowed from -12.46% to -21.37% compared to the same period last year, operating (EBITDA) margins now -1,964.07% from -1,784.25%. Change in operating ... Read more (Read more...)
GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) is aiming for an EMA marketing green light for Epidiolex, its lead cannabidiol or CBD product candidate, designed adjunctively to treat seizures correlated with two incredibly formidable childhood-onset epilepsy conditions: Lennox-Gastaut syndrome (LGS) and Dravet syndrome, both forms highly resistant to treatment.
LONDON and CARLSBAD, Calif., Dec. 29, 2017-- GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid ...
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to GW Pharmaceuticals Plc Here are 5 ETFs with the largest exposure to GWPH-US. Comparing the performance and risk of GW Pharmaceuticals Plc with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
GW Pharmaceuticals plc said early Thursday that the Food and Drug Administration will review a new drug application for its cannabis-derived drug epidiolex for seizures associated with two rare types of ...
GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) investors will be smiling to hear the drug maker's good news today: FDA acceptance for filing with Priority Review of GWPH's NDA for the company's investigational seizure treatment Epidiolex (cannabidiol or CBD). The asset was designed to tackle two rare as well as challenging to treat conditions of childhood-onset epilepsy, Lennox-Gastaut syndrome (LGS) and Dravet syndrome. Worthy of note, the new year could prove to be a big year for this biotech player, considering the PDUFA (Prescription Drug User Fee Act) goal date for completion of the FDA review of the Epidiolex NDA is June 27, 2018.
LONDON and CARLSBAD, Calif., Dec. 28, 2017-- GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid ...
The FDA grants a fast track status to Insys' (INSY) cannabidiol oral solution for Prader-Willi syndrome. The company also plans to move the candidate into clinical development in first-quarter 2018.